Federal Register / Vol. 77, No. 150 / Friday, August 3, 2012 / Notices 46519 

within the vicinity of Los Banos, 

California. The general project location 

is south of State Route 152 between U.S. 

101 and Interstate 5, approximately two 

hours southeast from San Francisco. 

The RMP/GP area is owned by 

Reclamation and was built as part of the 

water storage and delivery system of 

reservoirs, aqueducts, power plants, and 

pumping stations operated under the 

California State Water Project and 

Central Valley Project. Construction 

began on San Luis Reservoir in 1963 

and was completed in 1967 with 

planned joint-use by the State Water 

Project and the Central Valley Project. 

The California Department of Parks and 

Recreation was given the responsibility 

to plan, design, construct, maintain, and 

operate the recreation areas surrounding 

the reservoirs. 

The new plan will: (1) Enhance 

natural resources and recreational 

opportunities without interrupting 

reservoir operations; (2) provide 

recreational opportunities to meet the 

demands of a growing population with 

diverse interests; (3) ensure diversity of 

recreational opportunities and quality of 

the recreational experience; (4) protect 

natural, cultural, and recreational 

sources while providing resource 

education opportunities and 

stewardship; and (5) provide updated 

management direction for establishing a 

new management agreement with the 

State of California. 

The Draft EIS/Revised Draft EIR 

outlines the formulation and evaluation 

of alternatives designed to address these 

issues through a representation of the 

varied interests at the Plan Area. The No 

Action/No Project Alternative 

(Alternative 1) would result in the 

continuation of current management 

practices. Action Alternative 2 (Limited 

New Access and Development) 

emphasizes resource protection and 

limited new development. Action 

Alternative 3 (Moderate New Access 

and Development) balances natural and 

cultural resource protection and 

recreation opportunities. Action 

Alternative 4 (Maximum New Access 

and Development) provides the most 

overall recreation facility development. 

The Draft RMP/GP EIS/EIR has been 

developed within the authorities 

provided by Congress through the 

Reclamation Recreation Management 

Act of 1992 (Pub. L. 102–575, Title 28, 

16 U.S.C. 460L) and other applicable 

agency and Department of the Interior 

policies. 

Copies of the Draft RMP/GP EIS/EIR 

are available for public review at the 

following locations: 

• Bureau of Reclamation, Mid-Pacific 

Region, Regional Library, 2800 Cottage 

Way, Sacramento, CA 95825. 

• Bureau of Reclamation, SouthCentral California Area Office, 1243 N 

Street, Fresno, CA 93721. 

• Four Rivers Sector Office, 31426 

Gonzaga Road, Gustine, CA 95322 

• Los Banos Library, 1312 South 7th 

Street, Los Banos, CA 93635. 

• California Department of Parks and 

Recreation, Northern Service Center, 

One Capitol Mall, Suite 500, 

Sacramento, CA 95814. 

• Bureau of Reclamation, Denver 

Office Library, Building 67, Room 167, 

Denver Federal Center, 6th and Kipling, 

Denver, CO 80225. 

• Natural Resources Library, U.S. 

Department of the Interior, 1849 C Street 

NW., Main Interior Building, 

Washington, DC 20240–0001. 

Public Meeting 

A brief presentation, including a 

project overview, will open the public 

meeting. This will be followed by an 

open house during which individual 

concerns and questions will be 

addressed through interaction with the 

project team. 

If special assistance is required at the 

public meeting, please contact Mr. Dave 

Woolley at 559–487–5049, (TTY 1–800– 

735–2929), or by emailing 

dwoolley@usbr.gov. Please notify Mr. 

Woolley as far in advance as possible to 

enable Reclamation staff enough time to 

secure the needed services. If a request 

cannot be honored, the requestor will be 

notified. 

Public Disclosure 

Before including your address, phone 

number, email address, or other 

personal identifying information in your 

comment, you should be aware that 

your entire comment—including your 

personal identifying information—may 

be made publicly available at any time. 

While you can ask us in your comment 

to withhold your personal identifying 

information from public review, we 

cannot guarantee that we will be able to 

do so. 

Dated: May 17, 2012. 

Pablo R. Arroyave, 

Deputy Regional Director, Mid-Pacific Region. 

[FR Doc. 2012–19021 Filed 8–2–12; 8:45 am] 

BILLING CODE 4310–MN–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–365] 

Proposed Aggregate Production 

Quotas for Schedule I and II Controlled 

Substances and Proposed 

Assessment of Annual Needs for the 

List I Chemicals Ephedrine, 

Pseudoephedrine, and 

Phenylpropanolamine for 2013 

AGENCY: Drug Enforcement 

Administration (DEA), Department of 

Justice. 

ACTION: Notice with request for 

comments. 

SUMMARY: This notice proposes initial 

year 2013 aggregate production quotas 

for controlled substances in schedules I 

and II of the Controlled Substances Act 

(CSA) and assessment of annual needs 

for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. 

DATES: Electronic comments must be 

submitted and written comments must 

be postmarked on or before September 

4, 2012. Commenters should be aware 

that the electronic Federal Docket 

Management System will not accept 

comments after midnight Eastern Time 

on the last day of the comment period. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–365’’ on all electronic and 

written correspondence. DEA 

encourages that all comments be 

submitted electronically through http:// 

www.regulations.gov using the 

electronic comment form provided on 

that site. An electronic copy of this 

document is also available at the http:// 

www.regulations.gov Web site for easy 

reference. Paper comments that 

duplicate the electronic submission are 

not necessary as all comments 

submitted to http://www.regulations.gov 

will be posted for public review and are 

part of the official docket record. 

Written comments submitted via regular 

or express mail should be sent to the 

Drug Enforcement Administration, 

Attention: DEA Federal Register 

Representative/ODL, 8701 Morrissette 

Drive, Springfield, VA 22152. 

FOR FURTHER INFORMATION CONTACT: John 

W. Partridge, Chief, Liaison and Policy 

Section, Drug Enforcement 

Administration, 8701 Morrissette Drive, 

Springfield, VA 22152, Telephone: (202) 

307–4654. 

SUPPLEMENTARY INFORMATION: 


TKELLEY on DSK3SPTVN1PROD with NOTICES
46520 Federal Register / Vol. 77, No. 150 / Friday, August 3, 2012 / Notices 

Posting of Public Comments 

Please note that all comments 

received are considered part of the 

public record and made available for 

public inspection online at http:// 

www.regulations.gov and in the DEA’s 

public docket. Such information 

includes personal identifying 

information (such as your name, 

address, etc.) voluntarily submitted by 

the commenter. 

If you want to submit personal 

identifying information (such as your 

name, address, etc.) as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘PERSONAL IDENTIFYING 

INFORMATION’’ in the first paragraph 

of your comment. You must also place 

all the personal identifying information 

you do not want posted online or made 

available in the public docket in the first 

paragraph of your comment and identify 

what information you want redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘CONFIDENTIAL BUSINESS 

INFORMATION’’ in the first paragraph 

of your comment. You must also 

prominently identify confidential 

business information to be redacted 

within the comment. If a comment has 

so much confidential business 

information that it cannot be effectively 

redacted, all or part of that comment 

may not be posted online or made 

available in the public docket. 

Personal identifying information and 

confidential business information 

identified and located as set forth above 

will be redacted, and the comment, in 

redacted form, will be posted online and 

placed in the DEA’s public docket file. 

Please note that the Freedom of 

Information Act applies to all comments 

received. If you wish to inspect the 

agency’s public docket file in person by 

appointment, please see the FOR

FURTHER INFORMATION CONTACT

paragraph. 

Background 

Section 306 of the CSA (21 U.S.C. 

826) requires the Attorney General to 

establish aggregate production quotas 

for each basic class of controlled 

substance listed in schedules I and II 

and for ephedrine, pseudoephedrine, 

and phenylpropanolamine. This 

responsibility has been delegated to the 

Administrator of the DEA by 28 CFR 

0.100. The Administrator, in turn, has 

redelegated this function to the Deputy 

Administrator, pursuant to 28 CFR 

0.104. 

The proposed year 2013 aggregate 

production quotas represent those 

quantities of schedule I and II controlled 

substances, and the list I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine, to be 

manufactured in the United States in 

2013 to provide for the estimated 

medical, scientific, research, and 

industrial needs of the United States, 

lawful export requirements, and the 

establishment and maintenance of 

reserve stocks. These quotas include 

imports of ephedrine, pseudoephedrine, 

and phenylpropanolamine but do not 

include imports of controlled 

substances for use in industrial 

processes. 

In determining the proposed 2013 

aggregate production quotas and 

assessment of annual needs, DEA has 

taken into account the criteria that DEA 

is required to consider in accordance 

with 21 U.S.C. 826(a), 21 CFR 1303.11 

(aggregate production quotas for 

controlled substances), and 21 CFR 

1315.11 (assessment of annual needs for 

ephedrine, pseudoephedrine, and 

phenylpropanolamine). DEA proposes 

the aggregate production quotas and 

assessment of annual needs for 2013 by 

considering (1) total net disposal of the 

class or chemical by all manufacturers 

and chemical importers during the 

current and two preceding years; (2) 

trends in the national rate of net 

disposal of the class or chemical; (3) 

total actual (or estimated) inventories of 

the class or chemical and of all 

substances manufactured from the class 

or chemical, and trends in inventory 

accumulation; (4) projected demand for 

such class or chemical as indicated by 

procurement and chemical import 

quotas requested pursuant to 21 CFR 

1303.12, 1315.32, and 1315.34; and (5) 

other factors affecting the medical, 

scientific, research, and industrial needs 

in the United States, lawful export 

requirements, and reserve stocks, as the 

Deputy Administrator finds relevant. 

Other factors DEA considered in 

calculating the aggregate production 

quotas, but not the assessment of annual 

needs, include product development 

requirements of both bulk and finished 

dosage form manufacturers, and other 

pertinent information. In determining 

the proposed 2013 assessment of annual 

needs, DEA used the calculation 

methodology previously described in 

the 2010 and 2011 assessment of annual 

needs (74 FR 60294 and 75 FR 79407, 

respectively). 

DEA also specifically considered that 

inventory allowances granted to 

individual manufacturers may not 

always result in the availability of 

sufficient quantities to maintain an 

adequate reserve stock pursuant to 21 

U.S.C. 826(a), as intended. See 21 CFR 

1303.24. This would be concerning if a 

natural disaster or other unforeseen 

event resulted in substantial disruption 

to the amount of controlled substances 

available to provide for legitimate 

public need. As such, DEA proposes to 

include in all schedule II aggregate 

production quotas, and certain schedule 

I aggregate production quotas (gammahydroxybutyric acid and 

tetrahydrocannabinols), an additional 

25% of the estimated medical, 

scientific, and research needs as part of 

the amount necessary to ensure the 

establishment and maintenance of 

reserve stocks. The resulting established 

aggregate production quota will reflect 

these included amounts. This action 

will not affect the ability of 

manufacturers to maintain inventory 

allowances as specified by regulation. 

DEA expects that maintaining this 

reserve in certain established aggregate 

production quotas will mitigate adverse 

public affects if an unforeseen event 

resulted in substantial disruption to the 

amount of controlled substances 

available to provide for legitimate 

public need, as determined by DEA. 

DEA does not anticipate utilizing the 

reserve in the absence of these 

circumstances. 

The Deputy Administrator, therefore, 

proposes that the year 2013 aggregate 

production quotas and assessment of 

annual needs for the following schedule 

I and II controlled substances and for 

the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine, expressed in 

grams of anhydrous acid or base, be 

established as follows: 


TKELLEY on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 150 / Friday, August 3, 2012 / Notices 46521 

Proposed 

2013 

quotas 

g 

Basic Class—Schedule I 

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) .................................................................................................. 45 

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ................................................................................................. 45 

1-[1-(2-Thienyl)cyclohexyl]piperidine ......................................................................................................................... 5 

1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH–200) .................................................................................... 45 

1-Butyl-3-(1-naphthoyl)indole (JWH–073) ................................................................................................................. 45 

1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR–18 and RCS–8) ............................................................... 45 

1-Hexyl-3-(1-naphthoyl)indole (JWH–019) ................................................................................................................ 45 

1-Methyl-4-phenyl-4-propionoxypiperidine ................................................................................................................. 2 

1-Pentyl-3-(1-naphthoyl)indole (JWH–018 and AM678) ........................................................................................... 45 

1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH–203) ................................................................................................. 45 

1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH–250) ............................................................................................. 45 

1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH–398) ................................................................................................. 45 

1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH–122) ................................................................................................ 45 

1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH–081) ............................................................................................ 45 

1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR–19, RCS–4) ......................................................................................... 45 

2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C–P) ........................................................................................ 15 

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E) ................................................................................................ 15 

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D) ............................................................................................. 15 

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N) ............................................................................................... 15 

2-(2,5-Dimethoxyphenyl)ethanamine (2C–H) ............................................................................................................ 15 

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C) .............................................................................................. 15 

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I) ................................................................................................... 15 

2,5-Dimethoxy-4-ethylamphetamine (DOET) ............................................................................................................ 12 

2,5-Dimethoxy-4-n-propylthiophenethylamine ........................................................................................................... 12 

2,5-Dimethoxyamphetamine ...................................................................................................................................... 12 

2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2) ..................................................................................... 15 

2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4) .............................................................................. 15 

3-Methylfentanyl ......................................................................................................................................................... 2 

3-Methylthiofentanyl ................................................................................................................................................... 2 

3,4-Methylenedioxyamphetamine (MDA) .................................................................................................................. 30 

3,4-Methylenedioxy-N-methylcathinone (methylone) ................................................................................................ 15 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ................................................................................................... 24 

3,4-Methylenedioxymethamphetamine (MDMA) ....................................................................................................... 35 

3,4-Methylenedioxypyrovalerone (MDPV) ................................................................................................................. 15 

3,4,5-Trimethoxyamphetamine .................................................................................................................................. 12 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ............................................................................................................ 12 

4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ....................................................................................................... 12 

4-Methoxyamphetamine ............................................................................................................................................ 88 

4-Methylaminorex ...................................................................................................................................................... 12 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ............................................................................................................ 12 

4-Methyl-N-methylcathinone (mephedrone) .............................................................................................................. 15 

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ............................................................................... 68 

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47, 497 C8-homolog) 53 

5-Methoxy-3,4-methylenedioxyamphetamine ............................................................................................................ 12 

5-Methoxy-N,N-diisopropyltryptamine ........................................................................................................................ 12 

5-Methoxy-N,N-dimethyltryptamine ........................................................................................................................... 10 

Acetyl-alpha-methylfentanyl ....................................................................................................................................... 2 

Acetyldihydrocodeine ................................................................................................................................................. 2 

Acetylmethadol .......................................................................................................................................................... 2 

Allylprodine ................................................................................................................................................................ 2 

Alphacetylmethadol .................................................................................................................................................... 2 

Alpha-ethyltryptamine ................................................................................................................................................ 12 

Alphameprodine ......................................................................................................................................................... 2 

Alphamethadol ........................................................................................................................................................... 2 

Alpha-methylfentanyl ................................................................................................................................................. 2 

Alpha-methylthiofentanyl ............................................................................................................................................ 2 

Alpha-methyltryptamine (AMT) .................................................................................................................................. 12 

Aminorex .................................................................................................................................................................... 12 

Benzylmorphine ......................................................................................................................................................... 2 

Betacetylmethadol ..................................................................................................................................................... 2 

Beta-hydroxy-3-methylfentanyl .................................................................................................................................. 2 

Beta-hydroxyfentanyl ................................................................................................................................................. 2 

Betameprodine ........................................................................................................................................................... 2 

Betamethadol ............................................................................................................................................................. 2 

Betaprodine ................................................................................................................................................................ 2 

Bufotenine .................................................................................................................................................................. 3 

Cathinone ................................................................................................................................................................... 12 

Codeine-N-oxide ........................................................................................................................................................ 602 

Desomorphine ............................................................................................................................................................ 5 


TKELLEY on DSK3SPTVN1PROD with NOTICES
46522 Federal Register / Vol. 77, No. 150 / Friday, August 3, 2012 / Notices 

Proposed 

2013 

quotas 

g 

Diethyltryptamine ....................................................................................................................................................... 12 

Difenoxin .................................................................................................................................................................... 50 

Dihydromorphine ........................................................................................................................................................ 3,300,000 

Dimethyltryptamine .................................................................................................................................................... 18 

Gamma-hydroxybutyric acid ...................................................................................................................................... 46,250,000 

Heroin ........................................................................................................................................................................ 25 

Hydromorphinol .......................................................................................................................................................... 54 

Hydroxypethidine ....................................................................................................................................................... 2 

Ibogaine ..................................................................................................................................................................... 5 

Lysergic acid diethylamide (LSD) .............................................................................................................................. 30 

Marihuana .................................................................................................................................................................. 21,000 

Mescaline ................................................................................................................................................................... 13 

Methaqualone ............................................................................................................................................................ 10 

Methcathinone ........................................................................................................................................................... 14 

Methyldihydromorphine .............................................................................................................................................. 2 

Morphine-N-oxide ...................................................................................................................................................... 655 

N-Benzylpiperazine .................................................................................................................................................... 12 

N,N-Dimethylamphetamine ........................................................................................................................................ 12 

N-Ethylamphetamine ................................................................................................................................................. 12 

N-Hydroxy-3,4-methylenedioxyamphetamine ............................................................................................................ 12 

Noracymethadol ......................................................................................................................................................... 2 

Norlevorphanol ........................................................................................................................................................... 52 

Normethadone ........................................................................................................................................................... 2 

Normorphine .............................................................................................................................................................. 18 

Para-fluorofentanyl ..................................................................................................................................................... 2 

Phenomorphan .......................................................................................................................................................... 2 

Pholcodine ................................................................................................................................................................. 2 

Properidine ................................................................................................................................................................. 2 

Psilocybin ................................................................................................................................................................... 2 

Psilocyn ...................................................................................................................................................................... 4 

Tetrahydrocannabinols .............................................................................................................................................. 491,000 

Thiofentanyl ............................................................................................................................................................... 2 

Tilidine ........................................................................................................................................................................ 10 

Trimeperidine ............................................................................................................................................................. 2 

Basic Class—Schedule II 

1-Phenylcyclohexylamine .......................................................................................................................................... 3 

1-Piperdinocyclohexanecarbonitrile ........................................................................................................................... 21 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ............................................................................................................... 2,250,000 

Alfentanil .................................................................................................................................................................... 38,250 

Alphaprodine .............................................................................................................................................................. 3 

Amobarbital ................................................................................................................................................................ 9 

Amphetamine (for conversion) .................................................................................................................................. 18,375,000 

Amphetamine (for sale) ............................................................................................................................................. 38,000,000 

Carfentanil .................................................................................................................................................................. 6 

Cocaine ...................................................................................................................................................................... 240,000 

Codeine (for conversion) ........................................................................................................................................... 81,250,000 

Codeine (for sale) ...................................................................................................................................................... 49,506,250 

Dextropropoxyphene .................................................................................................................................................. 19 

Dihydrocodeine .......................................................................................................................................................... 250,000 

Diphenoxylate ............................................................................................................................................................ 750,000 

Ecgonine .................................................................................................................................................................... 127,500 

Ethylmorphine ............................................................................................................................................................ 3 

Fentanyl ..................................................................................................................................................................... 2,108,750 

Glutethimide ............................................................................................................................................................... 3 

Hydrocodone (for sale) .............................................................................................................................................. 78,750,000 

Hydromorphone ......................................................................................................................................................... 4,535,000 

Isomethadone ............................................................................................................................................................ 5 

Levo-alphacetylmethadol (LAAM) .............................................................................................................................. 4 

Levomethorphan ........................................................................................................................................................ 6 

Levorphanol ............................................................................................................................................................... 4,500 

Lisdexamfetamine ...................................................................................................................................................... 19,250,000 

Meperidine ................................................................................................................................................................. 6,875,000 

Meperidine Intermediate-A ........................................................................................................................................ 6 

Meperidine Intermediate-B ........................................................................................................................................ 11 

Meperidine Intermediate-C ........................................................................................................................................ 6 

Metazocine ................................................................................................................................................................. 6 

Methadone (for sale) ................................................................................................................................................. 25,000,000 

Methadone Intermediate ............................................................................................................................................ 32,500,000 

Methamphetamine ..................................................................................................................................................... 3,912,500 


TKELLEY on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 150 / Friday, August 3, 2012 / Notices 46523 

Proposed 

2013 

quotas 

g 

[962,500 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,888,750 grams 

for methamphetamine mostly for conversion to a schedule III product; and 61,250 grams for methamphetamine (for sale)].

Methylphenidate ......................................................................................................................................................... 72,250,000 

Morphine (for conversion) .......................................................................................................................................... 103,750,000 

Morphine (for sale) .................................................................................................................................................... 51,250,000 

Nabilone ..................................................................................................................................................................... 25,628 

Noroxymorphone (for conversion) ............................................................................................................................. 9,000,000 

Noroxymorphone (for sale) ........................................................................................................................................ 508,750 

Opium (powder) ......................................................................................................................................................... 91,250 

Opium (tincture) ......................................................................................................................................................... 1,287,500 

Oripavine .................................................................................................................................................................... 22,750,000 

Oxycodone (for conversion) ...................................................................................................................................... 10,250,000 

Oxycodone (for sale) ................................................................................................................................................. 123,375,000 

Oxymorphone (for conversion) .................................................................................................................................. 16,000,000 

Oxymorphone (for sale) ............................................................................................................................................. 6,875,000 

Pentobarbital .............................................................................................................................................................. 42,500,000 

Phenazocine .............................................................................................................................................................. 6 

Phencyclidine ............................................................................................................................................................. 30 

Phenmetrazine ........................................................................................................................................................... 3 

Phenylacetone ........................................................................................................................................................... 20,000,000 

Racemethorphan ....................................................................................................................................................... 3 

Remifentanil ............................................................................................................................................................... 2,500 

Secobarbital ............................................................................................................................................................... 215,003 

Sufentanil ................................................................................................................................................................... 6,250 

Tapentadol ................................................................................................................................................................. 13,500,000 

Thebaine .................................................................................................................................................................... 145,000,000 

Basic Class—List I Chemicals 

Ephedrine (for conversion) ........................................................................................................................................ 12,000,000 

Ephedrine (for sale) ................................................................................................................................................... 3,200,000 

Phenylpropanolamine (for conversion) ...................................................................................................................... 25,700,000 

Phenylpropanolamine (for sale) ................................................................................................................................. 4,400,000 

Pseudoephedrine (for sale) ....................................................................................................................................... 185,000,000 

The Deputy Administrator further 

proposes that aggregate production 

quotas for all other schedule I and II 

controlled substances included in 21 

CFR 1308.11 and 1308.12 be established 

at zero. Pursuant to 21 CFR 1303.13 and 

21 CFR 1315.13, upon consideration of 

the relevant factors, the Deputy 

Administrator may adjust the 2013 

aggregate production quotas and 

assessment of annual needs as needed. 

Comments 

Pursuant to 21 CFR 1303.11 and 21 

CFR 1315.11, any interested person may 

submit written comments on or 

objections to these proposed 

determinations. Based on comments 

received in response to this Notice, the 

Deputy Administrator may hold a 

public hearing on one or more issues 

raised. In the event the Deputy 

Administrator decides in his sole 

discretion to hold such a hearing, the 

Deputy Administrator will publish a 

notice of any such hearing in the 

Federal Register. After consideration of 

any comments and after a hearing, if one 

is held, the Deputy Administrator will 

publish in the Federal Register a final 

order establishing the 2013 aggregate 

production quota for each basic class of 

controlled substance and assessment of 

annual needs for the list I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine. 

Dated: July 31, 2012. 

Thomas M. Harrigan, 

Deputy Administrator. 

[FR Doc. 2012–19052 Filed 8–2–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Office of the Secretary 

Agency Information Collection 

Activities; Submission for OMB 

Review; Comment Request; Prohibited 

Transaction Class Exemption for 

Cross-Trades of Securities by Index 

and Model-Driven Funds 

ACTION: Notice. 

SUMMARY: The Department of Labor 

(DOL) is submitting the Employee 

Benefits Security Administration 

(EBSA) sponsored information 

collection request (ICR) titled, 

‘‘Prohibited Transaction Class 

Exemption for Cross-Trades of 

Securities by Index and Model-Driven 

Funds,’’ to the Office of Management 

and Budget (OMB) for review and 

approval for continued use in 

accordance with the Paperwork 

Reduction Act (PRA) of 1995 (44 U.S.C. 

3501 et seq.). 

DATES: Submit comments on or before 

September 4, 2012. 

ADDRESSES: A copy of this ICR with 

applicable supporting documentation; 

including a description of the likely 

respondents, proposed frequency of 

response, and estimated total burden 

may be obtained from the RegInfo.gov 

Web site, http://www.reginfo.gov/ 

public/do/PRAMain, on the day 

following publication of this notice or 

by contacting Michel Smyth by 

telephone at 202–693–4129 (this is not 

a toll-free number) or sending an email 

to DOL_PRA_PUBLIC@dol.gov. 

Submit comments about this request 

to the Office of Information and 


TKELLEY on DSK3SPTVN1PROD with NOTICES